For example, tumour-infiltrating lymphocytes are predictive of neoadjuvant treatment responses and improved overall survival in triple negative breast cancer (TNBC) and HER2-positive breast cancer, but are associated with an adverse survival in luminal HER2-negative breast cancer8–11. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.